article thumbnail

This week in drug discovery (2-6 October)  

Drug Discovery World

In celebration of the Nobel Prize for Medicine going to two of the early proponents of mRNA technology for creating therapeutics, Katalin Karikó and Drew Weissman, this week our round-up highlights the importance of genetics, genomics and gene editing in drug discovery.

Drugs 52
article thumbnail

Right on target: The shift to precision pharmaceuticals

Drug Discovery World

Its convergence with genomics makes sense and we have now multiple examples of AI being used to inform prescribing, diagnostics and drug discovery/ development. The team utilised genomic data from a database consisting of over 11,000 patients and which represented 33 types of human cancers. Disappointing, but work is continuing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Dose: DDW’s drug discovery highlights

Drug Discovery World

Other research updates include a study by NIH 5 researchers using post-mortem brain tissues to understand genomic differences in individuals with attention deficit hyperactivity disorder. The study advances our understanding of ADHD by showing how the condition is tied to changes in how certain genes are expressed in the brain.

Drugs 52
article thumbnail

Podcast: What trends will speed up the journey from clinic to bedside?

Drug Discovery World

They are called: Sitting down with… PharmEnable , Is single-cell gene expression the next trend in next generation sequencing? In the second article, we hear from Dr Dina Finan, PhD, Product Manager at 10x Genomics and Dr Nick Downey, PhD, NGS Collaborations Lead at Integrated DNA Technologies.

article thumbnail

What the Glycome Can Tell Us About Persistent HIV Infection

XTalks

Xtalks spoke to lead author on the study, Mohamed Abdel-Mohsen, PhD, assistant professor, Vaccine & Immunotherapy Center at the Wistar Institute, about the emerging utility of identifying glycomic, or sugar, signatures on the surface of immune cells to help in their identification and potential targeting.

RNA 52
article thumbnail

The future outlook for mRNA therapies

Drug Discovery World

The biggest growth driver for mRNA therapeutics came from the Covid-19 pandemic, when mRNA-based vaccines proved effective in treating SARS-CoV-2, and pharmaceutical companies such as Pfizer/BioNTech and Moderna were successful in bringing these treatments to market. mRNA is a molecule made up of a single strand of ribonucleic acid (RNA).

RNA 52
article thumbnail

Roche-UCB’s $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures

Delveinsight

Genome-tuning’ biotech Omega Therapeutics snags USD 85 Million. It will push a pipeline of treatments toward the clinic as well as bankroll the recognition of new targets for genomic medicines. Omega’s platform is designed to adjust gene expression to healthy levels rather than switching genes on and off.

Genome 52